María Dolores Caballero Barrigón

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

Gustaaf W. van Imhoff, Andrew McMillan, Matthew J. Matasar et al. · Journal of Clinical Oncology · 2017 · 231 citations

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

Anas Younes, Joshua Brody, Cecilia Carpio et al. · The Lancet Haematology · 2019 · 194 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia +8

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

Massimo Federico, María Dolores Caballero Barrigón, Luigi Marcheselli et al. · The Lancet Haematology · 2018 · 112 citations · Full text

Lymphoid Neoplasia, Medicine, Immunology +5

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Gustaaf W. van Imhoff, Andrew McMillan, Matthew J. Matasar et al. · Blood · 2014 · 25 citations · Full text

ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).

Olalekan O. Oluwole, Michael R. Bishop, Christian Gisselbrecht et al. · Journal of Clinical Oncology · 2018 · 25 citations